Biogen (BIIB) ROE - Return on Equity
Current and historical Return on Equity (ROE) values for Biogen (BIIB) over the last 10 years.
|Medical||Medical - Biomedical and Genetics||$66.607B||$11.449B|
|Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia, and a deep clinical pipeline ranging from Alzheimer's disease, lupus nephritis to neuropathic pain.|